Cited by 1,627PI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

The DOI matches its Crossref record; 20 of the 22 references it cites were found in a registry or an index.

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Open access

Berns, Katrien, Horlings, Hugo M., Hennessy, Bryan T., Madiredjo, Mandy, Hijmans, E. Marielle, Beelen, Karin, Linn, Sabine C., Gonzalez-Angulo, Ana Maria, Stemke-Hale, Katherine, Hauptmann, Michael, Beijersbergen, Roderick L., Mills, Gordon B., van de Vijver, Marc J., Bernards, René·2007·Cancer Cell

DOI 10.1016/j.ccr.2007.08.030

Open this paper in CoChat — free account Open PDF

Abstract

A large-scale RNA interference screen to discover genes involved in trastuzumab resistance in breast cancer identified only PTEN as a modulator of drug sensitivity. Oncogenic mutants of PIK3CA (activator of the same pathway and frequently mutated in breast cancer) also conferred resistance to trastuzumab in cell culture. In a cohort of 55 breast cancer patients, activation of the PI3K pathway, as judged by the presence of oncogenic PIK3CA mutations or low PTEN expression, was associated with poor prognosis after trastuzumab therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone. Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2007.08.030

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature Cell Biology · doi:10.1038/nature02371 · Cited by 1,080
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877

Flagged first, then by citations

Show all 22 references

2 of the 22 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 1,001

Trastuzumab in gastric cancer
Okines, A. F. C., & Cunningham, D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.003 · Cited by 76
Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling
Lee, K., Nam, K., Oh, S., Lim, J., Kim, Y., Lee, J. W., Yu, J., Ahn, S. H., Kim, S., Noh, D., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0479-6 · Cited by 74
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2022) · Cancers · doi:10.3390/cancers14163996 · Cited by 81
Catecholamine-Induced β2-Adrenergic Receptor Activation Mediates Desensitization of Gastric Cancer Cells to Trastuzumab by Upregulating MUC4 Expression
Shi, M., Yang, Z., Hu, M., Liu, D., Hu, Y., Qian, L., Zhang, W., Chen, H., Guo, L., Yu, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202364 · Cited by 73
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages
Zhou, J. X., Yang, H., Deng, Q., Gu, X., He, P., Lin, Y., Zhao, M., Jiang, J., Chen, H., Lin, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds626 · Cited by 73
The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
Tormo, E., Adam‐Artigues, A., Ballester, S., Pineda, B., Zazo, S., Gónzález-Alonso, P., Albanell, J., Rovira, A., Rojo, F., Lluch, A. M., et al. (2017) · Scientific Reports · doi:10.1038/srep41309 · Cited by 73
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters
Lim, S. B., Lim, C. T., & Lim, W. (2019) · Cancers · doi:10.3390/cancers11101595 · Cited by 73
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations
Banneau, G., Guedj, M., MacGrogan, G. M., de Mascarel, I., Velasco, V., Schiappa, R., Bonadona, V., David, A., Dugast, C., Gilbert‐Dussardier, B., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2626 · Cited by 72
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
Ebbesen, S. H., Scaltriti, M., Bialucha, C. U., Morse, N., Kastenhuber, E. R., Wen, H. Y., Dow, L. E., Baselga, J. M., & Lowe, S. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523693113 · Cited by 73
Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics
Lee, A. J. X., & Swanton, C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.008 · Cited by 70
Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Sareyeldin, R. M., Gupta, I., Al‐Hashimi, I., Al-Thawadi, H., Farsi, H. F. A., Vranić, S., & Moustafa, A. A. (2019) · Cancers · doi:10.3390/cancers11050646 · Cited by 76
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
Guo, S., Loibl, S., von Minckwitz, G., Darb‐Esfahani, S., Lederer, B., & Denkert, C. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2019.497 · Cited by 71
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
Raja, S. M., Clubb, R. J., Bhattacharyya, M., Dimri, M., Cheng, H., Pan, W., Ortega-Cava, C. F., Reddi, A. L., Naramura, M., Band, V., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6585 · Cited by 71
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
Joshi, J. P., Brown, N. E., Griner, S. E., & Nahta, R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.082 · Cited by 71
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., & Martini, M. (2013) · Oncogene · doi:10.1038/onc.2013.265 · Cited by 70
Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients
Horlings, H. M., Lai, C., Nuyten, D. S. A., Halfwerk, H., Kristel, P., van Beers, E., Joosse, S. A., Klijn, C. N., Nederlof, P. M., Reinders, M. J. T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0709 · Cited by 71
Molecular classification of solid tumours: towards pathway-driven therapeutics
Swanton, C., & Caldas, C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605031 · Cited by 71
PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways
Zhao, Y., Montminy, T., Azad, T., Lightbody, E. D., Hao, Y., Sengupta, S., Asselin, É., Nicol, C. J. B., & Yang, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0593 · Cited by 72
Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
Schrock, A. B., Pavlick, D. C., Klempner, S. J., Chung, J., Forcier, B., Welsh, A. W., Young, L., Leyland-Jones, B., Bordoni, R. E., Carvajal, R. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3103 · Cited by 71
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification
Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., & Nakagawa, K. (2011) · Oncogene · doi:10.1038/onc.2011.111 · Cited by 70
Targeting the EGFR and the PKB pathway in cancer
Klein, S., & Levitzki, A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.006 · Cited by 70
Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence
Nanjundan, M., Byers, L. A., Carey, M. S., Siwak, D. R., Raso, M. G., Diao, L., Wang, J., Coombes, K. R., Roth, J. A., Mills, G. B., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f2a266 · Cited by 68
The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies
Fokas, E., McKenna, W. G., & Muschel, R. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9394-4 · Cited by 70
PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Stern, H. M., Gardner, H., Burzykowski, T., Elatre, W. A., O'Brien, C. L., Lackner, M. R., Pestano, G. A., Santiago, A., Villalobos, I. E., EIERMANN, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2993 · Cited by 70
Emerging therapeutic targets in metastatic progression: A focus on breast cancer
Li, Z., & Kang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.003 · Cited by 71
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the ‘PTP-ome'Preprint
Lin, G., Aranda, V., Muthuswamy, S. K., & Tonks, N. K. (2011) · Genes & Development · doi:10.1101/gad.2018911 · Cited by 70
Stemming Resistance to HER-2 Targeted Therapy
Bedard, P. L., Cardoso, F., & Piccart, M. J. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9116-x · Cited by 68
Systems pathology—taking molecular pathology into a new dimension
Faratian, D., Clyde, R. G., Crawford, J. W., & Harrison, D. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.102 · Cited by 71
Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Zhang, Z., Wang, J., Ji, D., Wang, C., Liu, R., Wu, Z., Liu, L., Zhu, D., Chang, J., Geng, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3396 · Cited by 69
IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation
Ikink, G. J., Boer, M., Bakker, E. R. M., & Hilkens, J. (2016) · Nature Communications · doi:10.1038/ncomms13567 · Cited by 69
Precision medicine in breast cancer: reality or utopia?
Bettaı̈eb, A., Paul, C., Plenchette, S., Shan, J., Chouchane, L., & Ghiringhelli, F. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1239-z · Cited by 69
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
Wu, X., Yang, H., Yu, X., & Qin, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1012552 · Cited by 76
Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance
Nahta, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320691 · Cited by 68
Personalized therapies in the cancer "omics" era
Ocaña, A., & Pandiella, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-202 · Cited by 68
HER2 breast cancer therapies: a review
Modi, S., & Murphy, C. G. (2009) · Biologics · doi:10.2147/btt.2009.3250 · Cited by 69
AKT signaling in ERBB2-amplified breast cancer
Carmona, F. J., Montemurro, F., Kannan, S., Rossi, V., Verma, C. S., Baselga, J. M., & Scaltriti, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.013 · Cited by 70
An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation
Smit, L., Berns, K., Spence, K., Ryder, W. D. J., Zeps, N., Madiredjo, M., Beijersbergen, R. L., Bernards, R., & Clarke, R. B. (2015) · Oncotarget · doi:10.18632/oncotarget.6354 · Cited by 68
Recent advances in novel targeted therapies for HER2-positive breast cancer
Murphy, C. G., & Morris, P. G. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328352d292 · Cited by 67
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Bekaii‐Saab, T., Wesolowski, R., Ahn, D. H., Wu, C. S.-Y., Mortazavi, A., Lustberg, M. B., Ramaswamy, B., Fowler, J. M., Wei, L., Overholser, J. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3997 · Cited by 67
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 75
Functional Toxicogenomics: Mechanism-Centered Toxicology
North, M. R., & Vulpe, C. D. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11124796 · Cited by 67
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance
Veeraraghavan, J., Angelis, C. D., Reis-Filho, J. S., Pascual, T., Prat, A., Rimawi, M. F., Osborne, C. K., & Schiff, R. (2017) · The Breast · doi:10.1016/j.breast.2017.06.022 · Cited by 67
Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway
Kumar, D., Haldar, S., Gorain, M., Kumar, S., Mulani, F. A., Yadav, A. S., Miele, L., Thulasiram, H. V., & Kundu, G. C. (2018) · BMC Cancer · doi:10.1186/s12885-017-3876-2 · Cited by 67
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Perez, E. A., de Haas, S. L., EIERMANN, W., Barrios, C. H., Toi, M., Im, Y., Conte, P., Martín, M., Pieńkowski, T., Pivot, X. B., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5687-0 · Cited by 67
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
De, P. K. R., Hasmann, M., & Leyland-Jones, B. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.006 · Cited by 66
Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
Hortobágyi, G. N. (2015) · Neoplasia · doi:10.1016/j.neo.2015.01.005 · Cited by 67
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Blancafort, A., Giró‐Perafita, A., Oliveras, G., Palomeras, S., Turrado, C., Campuzano, Ó., Carrión-Salip, D., Massaguer, A., Brugada, R., Palafox, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131241 · Cited by 66
Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack
Bulfoni, M., Turetta, M., Ben, F. D., Loreto, C. D., Beltrami, A. P., & Cesselli, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101775 · Cited by 66
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
Lu, Y., Müller, M. M., Smith, D. M., Dutta, B., Komurov, K., Iadevaia, S., Ruths, D. A., Tseng, J.-T., Yu, S., Yu, Q., et al. (2011) · Oncogene · doi:10.1038/onc.2011.164 · Cited by 65
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 66
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64
Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
André, F., Delaloge, S., & Soria, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6877 · Cited by 65
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
Huang, J., Wang, S., Lyu, H., Cai, B., Yang, X., Wang, J., & Liu, B. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-134 · Cited by 64
Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis
Roarty, K. P., & Echeverria, G. V. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645698 · Cited by 67
PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Rasti, A. R., Guimarães-Young, A., Datko, F. M., Borges, V. F., Aisner, D. L., & Shagisultanova, E. I. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00370 · Cited by 66
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Okita, R., Mougiakakos, D., Ando, T., Mao, Y., Sarhan, D., Wennerberg, E., Seliger, B., Lundqvist, A., Mimura, K., & Kiessling, R. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102237 · Cited by 64
Linking somatic genetic alterations in cancer to therapeutics
Stuart, D. D., & Sellers, W. R. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.02.001 · Cited by 66
RhoJ Regulates Melanoma Chemoresistance by Suppressing Pathways That Sense DNA Damage
Ho, H., Aruri, J., Kapadia, R., Mehr, H., White, M. A., & Ganesan, A. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0775 · Cited by 64
Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer
Dirican, E., Akkіprіk, M., & Özer, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-4924-2 · Cited by 64
Dual HER2-targeted approaches in HER2-positive breast cancer
Ahn, E. R., & Vogel, C. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1781-y · Cited by 64
Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
Burnett, J., Körkaya, H., Ouzounova, M., Jiang, H., Conley, S. J., Newman, B. W., Sun, L., Connarn, J. N., Chen, C., Zhang, N., et al. (2015) · Scientific Reports · doi:10.1038/srep15821 · Cited by 64
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer
Zhao, M., Scott, S. M., Evans, K. W., Yuca, E., Saridogan, T., Zheng, X., Wang, H., Korkut, A., Pico, C. X. C., Demirhan, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3017 · Cited by 62
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A., Bachelot, T., Chan, S., Han, H., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 53
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling
WICKI, A. N., Mandalà, M., Massi, D., Taverna, D., Tang, H., Hemmings, B. A., & Xue, G. (2016) · Physiological Reviews · doi:10.1152/physrev.00024.2015 · Cited by 64
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
Fang, W., Zhao, S., Liang, Y., Yang, Y., Yang, L., Dong, X., Zhang, L., Shoufeng, W., Yang, Y., Yang, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0547 · Cited by 63
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
Guérin, M., Rezaï, K., Isambert, N., Campone, M., Autret, A., Pakradouni, J., Provansal, M., Camerlo, J., Sabatier, R., Bertucci, F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.025 · Cited by 62
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy
Kim, H. S., Shin, S., Beom, S., Jung, M., Choi, Y. Y., Son, T., Kim, H., Cheong, J., Hyung, W. J., Noh, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10115 · Cited by 61
Mechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 66
Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance
Zuo, Q., Liu, J. L., Zhang, J., Wu, M., Guo, L., & Liao, W. (2015) · Scientific Reports · doi:10.1038/srep11634 · Cited by 60
Targeting the PI3K Pathway for Cancer Therapy
Sadeghi, N., & Gerber, D. E. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.56 · Cited by 59
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
Okines, A. F. C., & Cunningham, D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12450246 · Cited by 60
Implications of stemness-related signaling pathways in breast cancer response to therapy
Angeloni, V., Tiberio, P., Appierto, V., & Daidone, M. G. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.08.004 · Cited by 61
Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer
Hashimoto, K., Tsuda, H., Koizumi, F., Shimizu, C., Yonemori, K., Ando, M., Kodaira, M., Yunokawa, M., Fujiwara, Y., & Tamura, K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu247 · Cited by 60
miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling
Wang, H., Li, Q., Niu, X., Wang, G., Zheng, S., Fu, G., & Wang, Z. (2016) · Oncology Letters · doi:10.3892/ol.2016.5388 · Cited by 60
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Cosimo, S. D., Appierto, V., Pizzamiglio, S., Tiberio, P., Iorio, M. V., Hilbers, F., de Azambuja, E., de la Peña, L., Izquierdo, M. A., Huober, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2507 · Cited by 60
Methylation-mediated gene silencing as biomarkers of gastric cancer: A review
Nakamura, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.11991 · Cited by 59
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
Lee-Hoeflich, S. T., Pham, T. Q., Dowbenko, D., Munroe, X., Lee, J., Li, L., Zhou, W., Haverty, P. M., Pujara, K., Stinson, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0062 · Cited by 59
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes
Gatza, M. L., Kung, H., Blackwell, K., Dewhirst, M. W., Marks, J. R., & Chi, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2899 · Cited by 59
Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens
Nahta, R., Shabaya, S., Ozbay, T., & Rowe, D. (2009) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569209790112337 · Cited by 60
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
Tolaney, S. M., Burris, H. A., Gartner, E. M., Mayer, I. A., Saura, C., Maurer, M., Ciruelos, E., García, A. A., Campana, F., Wu, B., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3248-4 · Cited by 59
Loss of ARID1A Activates ANXA1 , which Serves as a Predictive Biomarker for Trastuzumab Resistance
Berns, K., Sonnenblick, A., Gennissen, A. M. C., Brohée, S., Hijmans, E. M., Evers, B., Fumagalli, D., Desmedt, C., Loibl, S., Denkert, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2996 · Cited by 63
Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells
Yamaji, M., Ota, A., Wahiduzzaman, M., Karnan, S., Hyodo, T., Konishi, H., Tsuzuki, S., Hosokawa, Y., & Haniuda, M. (2017) · Cancer Medicine · doi:10.1002/cam4.1179 · Cited by 59
MPPa-PDT suppresses breast tumor migration/invasion by inhibiting Akt-NF-κB-dependent MMP-9 expression via ROS
Huang, L., Lin, H., Chen, Q., Yu, L., & Bai, D. (2019) · BMC Cancer · doi:10.1186/s12885-019-6374-x · Cited by 59
Current Opinions on Chemoresistance: An Overview
Hasan, S., Taha, R. Y., & Omri, H. E. (2018) · Bioinformation · doi:10.6026/97320630014080 · Cited by 59
Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer
Gonzalez-Angulo, A. M., Chen, H., Karuturi, M. S., Chávez‐MacGregor, M., Tsavachidis, S., Meric‐Bernstam, F., Do, K.-A., Hortobágyi, G. N., Thompson, P. A., Mills, G. B., et al. (2012) · Cancer · doi:10.1002/cncr.27608 · Cited by 58
Integrating molecular diagnostics into anticancer drug discovery
Peták, I., Schwab, R. E., Őrfi, L., Kopper, L., & Kéri, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3135 · Cited by 58
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
Tamaskovic, R., Schwill, M., Nagy‐Davidescu, G., Jöst, C., Schaefer, D. C., Verdurmen, W. P. R., Schaefer, J. V., Honegger, A., & Plückthun, A. (2016) · Nature Communications · doi:10.1038/ncomms11672 · Cited by 58
Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers
Fang, L., Liu, Q., Cui, H., Zheng, Y., & Wu, C. (2022) · Genes · doi:10.3390/genes13040654 · Cited by 57
The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
Lee, J. Y., Hong, M. E., Kim, S. T., Park, S. H., Kang, W. K., Kim, K.-M., & Lee, J. (2015) · Scientific Reports · doi:10.1038/srep09289 · Cited by 57
“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?
Margariti, N., Fox, S. B., Bottini, A., & Generali, D. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0986-9 · Cited by 57
Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA
Tang, Y., Hamed, H. A., Cruickshanks, N. A., Fisher, P. B., Grant, S., & Dent, P. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076851 · Cited by 59
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
Díaz-Serrano, A., Angulo, B., Dominguez, C., Pazo-Cid, R., Salud, A., Jiménez‐Fonseca, P., León, A., Galan, M. C., Alsina, M., Rivera, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0379 · Cited by 57
Understanding and circumventing resistance to anticancer monoclonal antibodies
Reslan, L., Dalle, S., & Dumontet, C. (2009) · mAbs · doi:10.4161/mabs.1.3.8292 · Cited by 57
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Bao, Y., Oguz, G., Lee, W. C., Lee, P. L., Ghosh, K., Li, J., Wang, P., Lobie, P. E., Ehmsen, S., Ditzel, H. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19704-x · Cited by 58
Impact of Genomics on Personalized Cancer Medicine
Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 57
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
Sakai, H., Tsurutani, J., Iwasa, T., Komoike, Y., Sakai, K., Nishio, K., & Nakagawa, K. (2018) · Breast Cancer · doi:10.1007/s12282-018-0861-9 · Cited by 59
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Denkert, C., Lambertini, C., Fasching, P. A., Pogue–Geile, K. L., Mano, M. S., Untch, M., Wolmark, N., Huang, C., Loibl, S., Mamounas, E. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1989 · Cited by 55
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
Boulbés, D. R., Chauhan, G. B., Jin, Q., Bartholomeusz, C., & Esteva, F. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3414-3 · Cited by 55
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
Crawford, A. C., & Nahta, R. (2011) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569211796957584 · Cited by 55
Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
Zindy, P. J., Bergé, Y., Allal, B., Filleron, T., Pierredon, S., Cammas, A., Beck, S., Mhamdi, L., Li, F., Favre, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0420 · Cited by 55

Authors: Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., Beijersbergen, R. L., Mills, G. B., van de Vijver, M. J., & Bernards, R.
Affiliations: The Netherlands Cancer Institute (NL)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Bernards, René
ORCID: Berns, Katrien
Horlings, Hugo M.
Hennessy, Bryan T.
Hijmans, E. Marielle
Beelen, Karin
Linn, Sabine C.
Gonzalez-Angulo, Ana Maria
Hauptmann, Michael
Beijersbergen, Roderick L.
Mills, Gordon B.
Bernards, René
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2007-10
Volume: 12
Issue: 4
Pages: 395-402
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2007.08.030
OpenAlex: W2020372547
Cited by: 1,627
References: 22
Citations by year: 2026: 26 · 2025: 44 · 2024: 33 · 2023: 81 · 2022: 69 · 2021: 54 · 2020: 63 · 2019: 70 · 2018: 88 · 2017: 74 · 2016: 102 · 2015: 116 · 2014: 118 · 2013: 144 · 2012: 123
FWCI: 37.98
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2116 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Funders: National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: trastuzumab resistance, breast cancer, PI3K signaling, PTEN, PIK3CA mutation, RNAi screen, drug sensitivity, prognostic factors, HER2-positive breast cancer, treatment response prediction
MeSH terms: Trastuzumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Transduction, Genetic, Biomarkers, Tumor, Cohort Studies, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Disease Progression, Patient Selection, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, PTEN Phosphohydrolase, Kaplan-Meier Estimate, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks